NCT07544056 2026-04-22
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
BeBetter Med Inc
Phase 2/3 Not yet recruiting
BeBetter Med Inc
Bristol-Myers Squibb
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Semmelweis University
Shengjing Hospital
Cambridge University Hospitals NHS Foundation Trust
The Netherlands Cancer Institute
ERYtech Pharma
Tianjin Medical University Cancer Institute and Hospital
The Netherlands Cancer Institute
Celgene
GBG Forschungs GmbH